232 related articles for article (PubMed ID: 3130094)
1. Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro.
Runge MS; Bode C; Matsueda GR; Haber E
Biochemistry; 1988 Feb; 27(4):1153-7. PubMed ID: 3130094
[TBL] [Abstract][Full Text] [Related]
2. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo.
Runge MS; Bode C; Matsueda GR; Haber E
Proc Natl Acad Sci U S A; 1987 Nov; 84(21):7659-62. PubMed ID: 3118374
[TBL] [Abstract][Full Text] [Related]
3. Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator.
Bode C; Runge MS; Schönermark S; Eberle T; Newell JB; Kübler W; Haber E
Circulation; 1990 Jun; 81(6):1974-80. PubMed ID: 2111744
[TBL] [Abstract][Full Text] [Related]
4. Antibody-directed fibrinolysis. An antibody specific for both fibrin and tissue plasminogen activator.
Bode C; Runge MS; Branscomb EE; Newell JB; Matsueda GR; Haber E
J Biol Chem; 1989 Jan; 264(2):944-8. PubMed ID: 2492021
[TBL] [Abstract][Full Text] [Related]
5. Hybrid molecules: insights into plasminogen activator function.
Runge MS; Bode C; Haber E; Quertermous T
Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766
[TBL] [Abstract][Full Text] [Related]
6. Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator.
Branscomb EE; Runge MS; Savard CE; Adams KM; Matsueda GR; Haber E
Thromb Haemost; 1990 Oct; 64(2):260-6. PubMed ID: 2125375
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of fibrinolysis by bispecific monoclonal antibodies reactive to fibrin and plasminogen activators.
Kurokawa T; Iwasa S; Kakinuma A
Thromb Res Suppl; 1990; 10():83-9. PubMed ID: 2107601
[TBL] [Abstract][Full Text] [Related]
8. Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase.
Hagemeyer CE; Tomic I; Weirich U; Graeber J; Nordt T; Runge MS; Bode C; Peter K
J Thromb Haemost; 2004 May; 2(5):797-803. PubMed ID: 15099287
[TBL] [Abstract][Full Text] [Related]
9. Characterization of an antibody-urokinase conjugate. A plasminogen activator targeted to fibrin.
Bode C; Runge MS; Newell JB; Matsueda GR; Haber E
J Biol Chem; 1987 Aug; 262(22):10819-23. PubMed ID: 3611093
[TBL] [Abstract][Full Text] [Related]
10. A bispecific antibody enhances the fibrinolytic potency of single-chain urokinase.
Charpie JR; Runge MS; Matsueda GR; Haber E
Biochemistry; 1990 Jul; 29(27):6374-8. PubMed ID: 1698452
[TBL] [Abstract][Full Text] [Related]
11. Antibody-directed fibrinolysis: a bispecific (Fab')2 that binds to fibrin and tissue plasminogen activator.
Runge MS; Bode C; Savard CE; Matsueda GR; Haber E
Bioconjug Chem; 1990; 1(4):274-7. PubMed ID: 2129015
[TBL] [Abstract][Full Text] [Related]
12. A bispecific antifibrin-antiplatelet urokinase conjugate (BAAUC) induces enhanced clot lysis and inhibits platelet aggregation.
Ruef J; Nordt TK; Peter K; Runge MS; Kübler W; Bode C
Thromb Haemost; 1999 Jul; 82(1):109-14. PubMed ID: 10456463
[TBL] [Abstract][Full Text] [Related]
13. Construction and expression of a recombinant antibody-targeted plasminogen activator.
Schnee JM; Runge MS; Matsueda GR; Hudson NW; Seidman JG; Haber E; Quertermous T
Proc Natl Acad Sci U S A; 1987 Oct; 84(19):6904-8. PubMed ID: 3116546
[TBL] [Abstract][Full Text] [Related]
14. Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin.
Dewerchin M; Lijnen HR; Van Hoef B; De Cock F; Collen D
Eur J Biochem; 1989 Oct; 185(1):141-9. PubMed ID: 2530085
[TBL] [Abstract][Full Text] [Related]
15. Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons.
Imura Y; Stassen JM; Kurokawa T; Iwasa S; Lijnen HR; Collen D
Blood; 1992 May; 79(9):2322-9. PubMed ID: 1571545
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
[TBL] [Abstract][Full Text] [Related]
17. Bispecific monoclonal antibodies increase the fibrin-specific fibrinolytic activity of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA).
Bos R; Nieuwenhuizen W
Ann N Y Acad Sci; 1992 Dec; 667():428-30. PubMed ID: 1309066
[No Abstract] [Full Text] [Related]
18. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
19. Antibody-directed urokinase: a specific fibrinolytic agent.
Bode C; Matsueda GR; Hui KY; Haber E
Science; 1985 Aug; 229(4715):765-7. PubMed ID: 4023710
[TBL] [Abstract][Full Text] [Related]
20. A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma.
Declerck PJ; Lijnen HR; Verstreken M; Moreau H; Collen D
Blood; 1990 May; 75(9):1794-800. PubMed ID: 1691934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
